Menu

Report Library

View More

Impact Events

More
Date Lead Company Event Type Approval Change Approval Likelihood
5/15/25 Merck & Co (MRK) Keytruda for Ovarian Cancer Subscribers Only Subscribers Only Subscribers Only
5/14/25 Arcellx (ACLX) Anito-cel for Multiple Myeloma (MM) Subscribers Only Subscribers Only Subscribers Only
5/13/25 iTeos (ITOS) Belrestotug for Non-Small Cell Lung Cancer (NSCLC) Subscribers Only Subscribers Only Subscribers Only
5/10/25 Novo Nordisk (NVO) Sogroya for Short Stature / Growth Hormone Deficiency Subscribers Only Subscribers Only Subscribers Only
5/9/25 AstraZeneca (AZN) Imfinzi for Bladder Cancer Subscribers Only Subscribers Only Subscribers Only

Upcoming Catalysts

More
Expected Date Range Lead Company Drug Expected Catalyst
04/01/2025 Subscribers Only Subscribers Only Company - Divestment/Spinoff
04/24/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update
05/09/2025 Subscribers Only Subscribers Only Trial Data - Updated Results
05/13/2025 Subscribers Only Subscribers Only Partnership - Acquisition Completion
05/13/2025 Subscribers Only Subscribers Only Partnership - Acquisition Completion